Emerging research suggest Sofix’s's Cagrilintide/GLP-1 offers a unique therapeutic method for targeting diabetes-related disorders. This molecule combination merges Cagrilintide, a selective GLP-1 receptor stimulator, with a established GLP-1 analogue. The expected synergistic effect could lead t